Steven D. Nathan, MD, FCCP

Treprostinil significantly slowed FVC decline and reduced clinical worsening events over 52 weeks in patients with IPF.

Steven D. Nathan, MD, FCCP, and Fernando J. Martinez, MD, MS, share clinical pearls and advice for the management of IPF.

Expert pulmonologists comment on emerging therapies in the pipeline for the treatment of IPF.

Fernando J. Martinez, MD, MS, and Steven D. Nathan, MD, FCCP, share their personal experiences using pirfenidone and nintedanib in clinical practice and discuss the role of managing comorbidities for the treatment of IPF.

Experts in pulmonology discuss the safety and efficacy of pirfenidone and nintedanib for the management of IPF.

Drs Fernando J. Martinez and Steven D. Nathan review the goals of therapy and the importance of non-pharmacological therapies for the management of IPF.

Steven D. Nathan, MD, FCCP, leads the discussion on the differential diagnosis of idiopathic pulmonary fibrosis (IPF).

Expert pulmonologists discuss the effect of early and late diagnosis on IPF disease management, as well as the importance of a multidisciplinary team approach to treatment.

Steven D. Nathan, MD, FCCP, provides an overview of idiopathic pulmonary fibrosis, including long-term disease complications and the effect on a patient’s quality of life.